Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Sylvia Annabel Dass, Rehasri Selva Rajan, Gee Jun Tye & Venugopal Balakrishnan. (2021) The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy. Human Vaccines & Immunotherapeutics 17:9, pages 2981-2994.
Read now
Read now
Angel Charles, Christopher M. Bourne, Tanya Korontsvit, Zita E. H. Aretz, Sung Soo Mun, Tao Dao, Martin G. Klatt & David A. Scheinberg. (2021) Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy. OncoImmunology 10:1.
Read now
Read now
Christian Jost, Diana Darowski, John Challier, Vesna Pulko, Lydia J Hanisch, Wei Xu, Ekkehard Mössner, Alexander Bujotzek, Stefan Klostermann, Pablo Umana, Roland E. Kontermann & Christian Klein. (2020) CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins. mAbs 12:1.
Read now
Read now
Tao Dao, Sung Soo Mun, Andrew C. Scott, Casey A. Jarvis, Tatyana Korontsvit, Zhiyuan Yang, Lianxing Liu, Martin G. Klatt, Manuel Guerreiro, Annamalai Selvakumar, Elliott J. Brea, Claire Oh, Cheng Liu & David A. Scheinberg. (2019) Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. OncoImmunology 8:7.
Read now
Read now
Devin B. Lowe, Camille K. Bivens, Alexis S. Mobley, Christian E. Herrera, Amanda L. McCormick, Timea Wichner, Manoj K. Sabnani, Laurence M. Wood & Jon A. Weidanz. (2017) TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets. mAbs 9:4, pages 603-614.
Read now
Read now
Articles from other publishers (34)
Even Walseng, Bo Wang, Chunning Yang, Pooja Patel, Chihao Zhao, Hanzhi Zhang, Peng Zhao & Yariv Mazor. (2023) Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers. Frontiers in Immunology 14.
Crossref
Crossref
Xinbo Yang, Daisuke Nishimiya, Sara Löchte, Kevin M. Jude, Marta Borowska, Christina S. Savvides, Michael Dougan, Leon Su, Xiang Zhao, Jacob Piehler & K. Christopher Garcia. (2023) Facile repurposing of peptide–MHC-restricted antibodies for cancer immunotherapy. Nature Biotechnology 41:7, pages 932-943.
Crossref
Crossref
Linghui Qian, Xuefen Lin, Xue Gao, Rizwan Ullah Khan, Jia-Yu Liao, Shubo Du, Jingyan Ge, Su Zeng & Shao Q. Yao. (2023) The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics. Chemical Reviews 123:12, pages 7782-7853.
Crossref
Crossref
Walter Bodmer & Vita Golubovskaya. (2023) Cancer Immunotherapy: Where Next?. Cancers 15:8, pages 2358.
Crossref
Crossref
Ilja E. Shapiro & Michal Bassani-Sternberg. (2023) The impact of immunopeptidomics: From basic research to clinical implementation. Seminars in Immunology 66, pages 101727.
Crossref
Crossref
Sacha Zinn, Rodrigo Vazquez-Lombardi, Carsten Zimmermann, Puja Sapra, Lutz Jermutus & Daniel Christ. (2023) Advances in antibody-based therapy in oncology. Nature Cancer 4:2, pages 165-180.
Crossref
Crossref
Takamitsu Hattori, Lorenzo Maso, Kiyomi Y. Araki, Akiko Koide, James Hayman, Padma Akkapeddi, Injin Bang, Benjamin G. Neel & Shohei Koide. (2023) Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy. Cancer Discovery 13:1, pages 132-145.
Crossref
Crossref
Hans-Peter Gerber & Leonard G. Presta. (2022) TCR mimic compounds for pHLA targeting with high potency modalities in oncology. Frontiers in Oncology 12.
Crossref
Crossref
Patrick A. Baeuerle & Holger Wesche. (2022) T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities. Current Opinion in Oncology 34:5, pages 552-558.
Crossref
Crossref
Christopher M. Bourne, Sung Soo Mun, Tao Dao, Zita E. H. Aretz, Zaki Molvi, Ron S. Gejman, Andrew Daman, Katsuyoshi Takata, Christian Steidl, Martin G. Klatt & David A. Scheinberg. (2022) Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment. Blood Advances 6:14, pages 4107-4121.
Crossref
Crossref
Chang Liu, Hong Liu, Moumita Dasgupta, Lance M. Hellman, Xiaogang Zhang, Kai Qu, Hui Xue, Yun Wang, Fenling Fan, Qi Chang, Duo Yu, Linhu Ge, Yu Zhang, Ziyou Cui, Pengbo Zhang, Bradley Heller, Hongbing Zhang, Bingyin Shi, Brian M. Baker & Cheng Liu. (2022) Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma. Scientific Reports 12:1.
Crossref
Crossref
Soroush Ghaffari, Katherine Upchurch-Ange, Susanne Gimlin, Trivendra Tripathi, Marjolein Sluijter, Jim Middelburg, Thorbald van Hall & Jon Weidanz. (2022) A Single-Domain TCR-like Antibody Selective for the Qa-1b/Qdm Peptide Complex Enhances Tumoricidal Activity of NK Cells via Blocking the NKG2A Immune Checkpoint. The Journal of Immunology 208:9, pages 2246-2255.
Crossref
Crossref
Shijie Jin, Yanping Sun, Xiao Liang, Xinyu Gu, Jiangtao Ning, Yingchun Xu, Shuqing Chen & Liqiang Pan. (2022) Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Zhijian Duan & Mitchell Ho. (2021) T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy. Molecular Cancer Therapeutics 20:9, pages 1533-1541.
Crossref
Crossref
Chrisann Kyi, Ekaterina Doubrovina, Qin Zhou, Sara Kravetz, Alexia Iasonos, Carol Aghajanian, Paul Sabbatini, David Spriggs, Richard J O'Reilly & Roisin E O’Cearbhaill. (2021) Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer. Journal for ImmunoTherapy of Cancer 9:8, pages e002752.
Crossref
Crossref
Vittoria Massafra, Sofia Tundo, Aline Dietzig, Axel Ducret, Christian Jost, Christian Klein, Roland E. Kontermann, Hendrik Knoetgen, Martin Steegmaier, Andrea Romagnani & Yvonne A. Nagel. (2021) Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells. The Journal of Immunology 207:2, pages 493-504.
Crossref
Crossref
Wen-Bin Zhao, Ying Shen, Wen-Hui Liu, Yi-Ming Li, Shi-Jie Jin, Ying-Chun Xu, Li-Qiang Pan, Zhan Zhou & Shu-Qing Chen. (2021) Soluble Expression of Fc-Fused T Cell Receptors Allows Yielding Novel Bispecific T Cell Engagers. Biomedicines 9:7, pages 790.
Crossref
Crossref
Velizar ShivarovGeorgi Blazhev. (2021) Bringing Together the Power of T Cell Receptor Mimic and Bispecific Antibodies for Cancer Immunotherapy: Still a Long Way to Go. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 40:2, pages 81-85.
Crossref
Crossref
Heather F. Jones, Zaki Molvi, Martin G. Klatt, Tao Dao & David A. Scheinberg. (2021) Empirical and Rational Design of T Cell Receptor-Based Immunotherapies. Frontiers in Immunology 11.
Crossref
Crossref
Carley Tasker, Jenny Patel, Vibha Jawa & Jad Maamary. (2021) Competition-Based Cell Assay Employing Soluble T Cell Receptors to Assess MHC Class II Antigen Processing and Presentation. The AAPS Journal 23:2.
Crossref
Crossref
Chi-Xiao Qiu, Xue-Fei Bai, Ying Shen, Zhan Zhou, Li-Qiang Pan, Ying-Chun Xu, Wen-Bin Zhao & Shu-Qing Chen. (2020) Specific Inhibition of Tumor Growth by T Cell Receptor–Drug Conjugates Targeting Intracellular Cancer-Testis Antigen NY-ESO-1/LAGE-1. Bioconjugate Chemistry 31:12, pages 2767-2778.
Crossref
Crossref
Nobuyuki Kurosawa, Aki Midorikawa, Kenta Ida, Yuka Wakata Fudaba & Masaharu Isobe. (2020) Development of a T‐cell receptor mimic antibody targeting a novel Wilms tumor 1‐derived peptide and analysis of its specificity. Cancer Science 111:10, pages 3516-3526.
Crossref
Crossref
Sebastian P. Haen, Markus W. Löffler, Hans-Georg Rammensee & Peter Brossart. (2020) Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nature Reviews Clinical Oncology 17:10, pages 595-610.
Crossref
Crossref
Lichen Zhu, Xiaomei Yang, Dani Zhong, Shenxia Xie, Wei Shi, Yangzi Li, Xiaoqiong Hou, HuaYao, Huihui Zhou, Minlong Zhao, Ziqiang Ding, Xinyue Zhao, Fengzhen Mo, Shihua Yin, Aiqun Liu & Xiaoling Lu. (2020) Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy. Journal of Immunology Research 2020, pages 1-8.
Crossref
Crossref
Ron S. Gejman, Heather F. Jones, Martin G. Klatt, Aaron Y. Chang, Claire Y. Oh, Smita S. Chandran, Tatiana Korontsvit, Viktoriya Zakahleva, Tao Dao, Christopher A. Klebanoff & David A. Scheinberg. (2020) Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform. Cancer Immunology Research 8:5, pages 672-684.
Crossref
Crossref
Qinghua He, Zhaoyu Liu, Zhihua Liu, Yuxiong Lai, Xinke Zhou & Jinsheng Weng. (2019) TCR-like antibodies in cancer immunotherapy. Journal of Hematology & Oncology 12:1.
Crossref
Crossref
Nobuyuki Kurosawa, Yuka Wakata, Kenta Ida, Aki Midorikawa & Masaharu Isobe. (2019) High throughput development of TCR-mimic antibody that targets survivin-2B80-88/HLA-A*A24 and its application in a bispecific T-cell engager. Scientific Reports 9:1.
Crossref
Crossref
Smita S. Chandran & Christopher A. Klebanoff. (2019) T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunological Reviews 290:1, pages 127-147.
Crossref
Crossref
Kate L. Lowe, David Cole, Rupert Kenefeck, Ita OKelly, Marco Lepore & Bent K. Jakobsen. (2019) Novel TCR-based biologics: mobilising T cells to warm ‘cold’ tumours. Cancer Treatment Reviews 77, pages 35-43.
Crossref
Crossref
Dale Johnson. (2018) Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies. International Journal of Molecular Sciences 19:11, pages 3685.
Crossref
Crossref
Jun Lai, Yun Wang, Shan-Shan Wu, Ding Ding, Ze-Yu Sun, Ying Zhang, Jie Zhou, Zhan Zhou, Ying-Chun Xu, Li-Qiang Pan & Shu-Qing Chen. (2018) Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1. Biomaterials 178, pages 158-169.
Crossref
Crossref
Jun Zhao, Ruth Nussinov, Wen-Jin Wu & Buyong Ma. (2018) In Silico Methods in Antibody Design. Antibodies 7:3, pages 22.
Crossref
Crossref
Paul J. Carter & Greg A. Lazar. (2017) Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Nature Reviews Drug Discovery 17:3, pages 197-223.
Crossref
Crossref
Aaron Y. Chang, Tao Dao, Ron S. Gejman, Casey A. Jarvis, Andrew Scott, Leonid Dubrovsky, Melissa D. Mathias, Tatyana Korontsvit, Victoriya Zakhaleva, Michael Curcio, Ronald C. Hendrickson, Cheng Liu & David A. Scheinberg. (2017) A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. Journal of Clinical Investigation 127:7, pages 2705-2718.
Crossref
Crossref